Zai LabZLAB +0.76%64 14-Day RSI is 52.86 as of Jun. 26, 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,424 Biotechnology companies, Zai Lab ranks worse than 72.05% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-06-26), Zai Lab's 14-Day RSI is 52.86.
The industry rank for Zai Lab's 14-Day RSI or its related term are showing as below:
ZLAB's 14-Day RSI is ranked worse than 72.05% of 1424
companies
in the Biotechnology industry
Industry Median: 45.5
vs ZLAB: 52.86
Zai Lab (NAS:ZLAB) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Zai Lab 14-Day RSI Related Terms
ZLAB vs TYRA, TRVI, OCUL: 14-Day RSI Comparison
For the Biotechnology subindustry, Zai Lab's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Zai Lab's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (ZLAB) has a 14-Day RSI of 52.86 as of Jun. 26, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #1026 out of 1424 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Zai Lab's 14-Day RSI too high?
Zai Lab's current 14-Day RSI is 52.86. The Biotechnology industry median 14-Day RSI is 45.50. Zai Lab's value of 52.86 is 16.2% above this industry median. Based on the distribution chart, Zai Lab ranks #1026 out of 1424 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's 14-Day RSI compare to TYRA and TRVI?
According to the Biotechnology industry distribution chart, Zai Lab ranks #1026 out of 1424 companies for 14-Day RSI. This places Zai Lab in the lower half of its industry. The industry median 14-Day RSI is 45.50. Zai Lab's value of 52.86 is 16.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.50, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current 14-Day RSI of 52.86 is 16.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Zai Lab and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current 14-Day RSI is 52.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.52 — trading 38.9% below its estimated fair value. The current 14-Day RSI is 52.86 and 16.2% above the Biotechnology industry median of 45.50. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Zai Lab (ZLAB), the current 14-Day RSI is 52.86 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $18.52 is trading 38.9% below its estimated GF Value™ of $30.30.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
14-Day RSI: 52.86
GF Value™: $30.30 vs. price of $18.52 (38.9% below fair value)
Industry Position: 16.2% above the Biotechnology median (#1026 of 1424)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 